Wren Capital
VC Fund
London, United Kingdom
Wren Capital is a VC fund in London focused on Biotechnology and Health Care. Wren is an angel investor in science, engineering and software. They founded Wren in 2011 and have invested in 50 companies so far.Wren is well known in the early stage investment community and has co-invested with a wide range of both angel and institutional investors. From software and semiconductors to genome editing, and from medical devices to satellites, they are interested in sectors where technical ingenuity and hard work can produce long term value. They look for people with a deep understanding of their markets. The founders they invest in are smart and they get things done. Wren typically invests £50,000 to £200,000 per funding round. Difficult problems take time to solve, so they are patient with their investments. Their aim is to get deals done and they take a pragmatic approach to doing so.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Wren Capital invests in
Stages Wren Capital invests in
Countries Wren Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.9M–$5M
- Series A
- $2.5M–$33M
- Venture - Series Unknown
- $1.1M–$8.9M
Investment Focus
Industry
- Biotechnology 16 (46%)
- Health Care 8 (23%)
- Medical 5 (14%)
- Medical Device 5 (14%)
- Biopharma 4 (11%)
Stage
- Seed 13 (37%)
- Series A 7 (20%)
- Venture - Series Unknown 6 (17%)
- Funding Round 3 (9%)
- Angel 2 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Rajat Malhotra
Managing Partner
|
Managing Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| SilVia Bio develops technologies to analyze and optimize mammalian cell factories used in biomanufacturing. The company focuses on identifying critical parameters that limit bioproduction yield and product quality in cell systems such as CHO and HEK cells. Its platform provides cell profiling services that generate interpretable data on manufacturing-relevant bottlenecks. Based on these insights, SilVia Bio designs and supplies precision media additives formulated to address specific rate-limiting cellular processes. The offerings are intended for biopharmaceutical and biomanufacturing teams seeking to improve titre, cell performance, and consistency in production processes. SilVia Bio also collaborates with industrial partners to apply its platform within real manufacturing environments. | $4M / Seed / Oct 15, 2026 | ||
| Singular Photonics is a startup that creates SPAD-based image sensors. | $2.2M / Seed / Aug 19, 2026 | ||
| SenseAIsoftware dramatically speeds up image acquisition while reducing sample damage from high-energy electron beams, offering up to 100x improvements in efficiency without loss of image integrity. | Seed / Sep 08, 2025 | ||
| Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system. | $1.1M / Venture - Series Unknown / Feb 25, 2025 | ||
| Spotta is the creator of an ultra-low-power insect monitoring sensor for detecting bed bug infestations. The company's sensor is battery-powered, allowing users to be notified whenever bed bugs are detected and analyzing the detection to ensure users are only notified about genuine incidents, allowing customers to prevent bed bugs fromentering the room and make treatment easier and less expensive. | $3.8M / Series A / Dec 15, 2023 | ||
| MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction. | $5M / Seed / Dec 13, 2023 | ||
| Bastion Therapeutics is a preclinical stage biotechnology startup that uses proprietary platform technology to boost Tregs for the immune system | $840K / Sep 12, 2023 | ||
| PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery of vital new medicines. | $7.5M / Seed / May 22, 2023 | ||
| MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction. | Seed / Apr 25, 2022 | ||
| Adapttech is a biomedical company that creates innovative, smart, and wearable technologies to assist people with physical disabilities in improving their quality of life. It aims to provide clinicians with better socket fitting and monitoring methods in order to improve the quality of life for people who have lost a lower limb. | $2.9M / Series A / Apr 06, 2022 | ||
| See all 35 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Wren Capital invest in?
Wren Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 35 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Wren Capital invest in?
Wren Capital typically joins rounds of $1.9M–$5M at Seed, $2.5M–$33M at Series A and $1.1M–$8.9M at Venture - Series Unknown. These are whole funding-round sizes, not Wren Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Wren Capital took part in.
How do I contact Wren Capital?
Public channels for Wren Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Wren Capital?
The team at Wren Capital includes Rajat Malhotra (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
